Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Wang, Qihui, Zhang, Yanfang, Wu, Lili, Niu, Sheng, Song, Chunli, Zhang, Zengyuan, Lu, Guangwen, Qiao, Chengpeng +6 more·2020·Cell
DOI 10.1016/j.cell.2020.03.045

Cited by (1,009)

Items 201–300 of 1,009

  1. Efforts at COVID-19 Vaccine Development: Challenges and Successes
    Azizul Haque, Anudeep B. Pant · 2020 · Vaccines
  2. The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis
    Nicholas A. Wong, Milton H. Saier · 2021 · International Journal of Molecular Sciences
  3. Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies
    Amira Mohammed Ali, Hiroshi Kunugi · 2021 · Molecules
  4. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies
    Adriana Albini, Giovanni Di Guardo, Douglas McClain Noonan, Michele Lombardo · 2020 · Internal and Emergency Medicine
  5. Toward Rapid and Sensitive Detection of SARS-CoV-2 with Functionalized Magnetic Nanoparticles
    Jing Zhong, Enja Laureen Rösch, Thilo Viereck, Meinhard Schilling, Frank Ludwig · 2021 · ACS Sensors
  6. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
    Yusuke Higuchi, Tatsuya Suzuki, Takao Arimori, Nariko Ikemura, Emiko Mihara, Yuhei Kirita, Eriko Ohgitani, Osam Mazda, Daisuke Motooka, Shota Nakamura et al. · 2021 · Nature Communications
  7. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19
    Francisco Tejerina, Pilar Catalán, Cristina Rodríguez‐Grande, Javier Adán‐Jiménez, Carmen Rodríguez, Patricia Muñóz, Teresa Aldámiz‐Echevarría, Cristina Díez, Leire Perez Latorre, Chiara Fanciulli et al. · 2022 · BMC Infectious Diseases
  8. Rationale for targeting complement in COVID‐19
    Anastasia Polycarpou, Mark C. Howard, Conrad A. Farrar, Roseanna Greenlaw, Giorgia Fanelli, Russell Wallis, Linda Sylvia Klavinskis, Steven Howard Sacks · 2020 · EMBO Molecular Medicine
  9. Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response
    Radhakrishnan Vishnubalaji, Hibah Shaath, Nehad M. Alajez · 2020 · Genes
  10. Risk Factors for Severity in Children with Coronavirus Disease 2019
    Tsabouri, Sophia, Makis, Alexandros, Kosmeri, Chrysoula, Siomou, Ekaterini · 2021 · Pediatric Clinics of North America
  11. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
    van Breemen, Richard B., Muchiri, Ruth N., Bates, Timothy A., Weinstein, Jules B., Leier, Hans C., Farley, Scotland, Tafesse, Fikadu G. · 2022 · Journal of Natural Products
  12. Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice
    Jesus A. Silvas, Desarey Morales Vasquez, Jun‐Gyu Park, Kevin Chiem, Anna Allué‐Guardia, Andreu Garcia‐Vilanova, Roy N. Platt, Lisa Miorin, Thomas Kehrer, Anastasija Čupić et al. · 2021 · Journal of Virology
  13. The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design
    Danielle C. Groves, Sarah Rowland‐Jones, Adrienn Angyal · 2020 · Biochemical and Biophysical Research Communications
  14. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus
    M. Dogan, L. Kozhaya, L. Placek, Courtney Gunter, Mesut Yi̇ği̇t, R. Hardy, Matthew Plassmeyer, Paige Coatney, Kimberleigh Lillard, Z. Bukhari et al. · 2021 · Communications Biology
  15. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses
    Jonas Nascimento Conde, William R. Schutt, Elena E. Gorbunova, Erich R. Mackow · 2020 · mBio
  16. SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets
    Palur Venkata Raghuvamsi, Nikhil Kumar Tulsian, Firdaus Samsudin, Xinlei Qian, Kiren Purushotorman, Yue Gu, Mary Kozma, Wong Y Hwa, Julien Lescar, Peter John Bond et al. · 2021 · eLife
  17. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction
    Wenpeng Cao, Chuqiao Dong, Seonghan Kim, Decheng Hou, Wanbo Tai, Lanying Du, Wonpil Im, Xiao Hui Zhang · 2021 · Biophysical Journal
  18. Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects
    Yousef Rasmi, Xiaokang Li, Johra Khan, Tuğba Özer, Jane Ru Choi · 2021 · Analytical and Bioanalytical Chemistry
  19. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
    Canrong Wu, Wanchao Yin, Yi Jiang, H. Eric Xu · 2022 · Acta Pharmacologica Sinica
  20. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies
    Ivan Mercurio, Vincenzo Tragni, Francesco Busto, Anna Grassi, Ciro Leonardo Pierri · 2020 · Cellular and Molecular Life Sciences
  21. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
    Fei Yu, Rong Xiang, Xiaoqian Deng, Lili Wang, Zhengsen Yu, Shijun Tian, Ruiying Liang, Yanbai Li, Tianlei Ying, Shibo Jiang · 2020 · Signal Transduction and Targeted Therapy
  22. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment
    Parastoo Tarighi, Samane Eftekhari, Milad Chizari, Mahsa Sabernavaei, Davod Jafari, Parastoo Mirzabeigi · 2021 · European Journal of Pharmacology
  23. The flexibility of ACE2 in the context of SARS-CoV-2 infection
    Emilia Pecora de Barros, Lorenzo Casalino, Zied Gaieb, Abigail C. Dommer, Yuzhang Wang, Lucy Fallon, Lauren E. Raguette, Kellon A. A. Belfon, Carlos L. Simmerling, Rommie E. Amaro · 2020 · Biophysical Journal
  24. The role of NO in COVID-19 and potential therapeutic strategies
    Wanyi Fang, Jingrui Jiang, Lei Su, Tong Shu, Huan Liu, Shenghan Lai, Reza Arman Ghiladi, Jun Wang · 2020 · Free Radical Biology and Medicine
  25. High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2
    Xiaotong Xue, Zihao Mi, Zhenzhen Wang, Zheng Pang, Hong Liu, Furen Zhang · 2020 · Journal of Investigative Dermatology
  26. Particulate Alum via Pickering Emulsion for an Enhanced COVID‐19 Vaccine Adjuvant
    Sha Peng, Fengqiang Cao, Yufei Xia, Xiao‐Dong Gao, Lianpan Dai, Jinghua Yan, Guanghui Ma · 2020 · Advanced Materials
  27. Kidney Function Indicators Predict Adverse Outcomes of COVID-19
    Ye-Mao Liu, Jing Xie, Ming-Ming Chen, Xiao Zhang, Xu Cheng, Haomiao Li, Feng Zhou, Juan-Juan Qin, Fang Lei, Ze Chen et al. · 2020 · Med
  28. Contributions of human ACE2 and TMPRSS2 in determining host–pathogen interaction of COVID-19
    Sabyasachi Senapati, Pratibha Banerjee, Sandilya Bhagavatula, Prem Prakash Kushwaha, Shashank Kumar · 2021 · Journal of Genetics
  29. GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein
    Ming Zhao, Yu Yu, Li-Ming Sun, Jia‐Qing Xing, Tingting Li, Yunkai Zhu, Miao Wang, Yin Yu, Wen Xue, Tian Xia et al. · 2021 · Nature Communications
  30. Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant
    Yamin Sun, Wenchao Lin, Wei Dong, Jianguo Xu · 2021 · Journal of Biosafety and Biosecurity
  31. SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders
    Narayanappa Amruta, Wesley H. Chastain, Meshi Paz, Rebecca J. Solch-Ottaiano, Isabel C. Murray-Brown, Jaime B. Befeler, Timothy E. Gressett, Michele T. Longo, Elizabeth B. Engler-Chiurazzi, Gregory Jaye Bix · 2021 · Cytokine & Growth Factor Reviews
  32. ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species
    Huan Yan, Hengwu Jiao, Qianyun Liu, Zhen Zhang, Qing Xiong, Bing-Jun Wang, Xin Wang, Ming Sen Guo, Lin‐Fa Wang, Ke Lan et al. · 2021 · Nature Ecology & Evolution
  33. The role of cell surface sialic acids for SARS-CoV-2 infection
    Xue‐Long Sun · 2021 · Glycobiology
  34. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry
    Julián Valero, Laia Civit, Daniel M. Dupont, Denis Selnihhin, Line Sinnathamby Reinert, Manja Idorn, Brett A. Israels, Aleksandra Bednarz, Claus Bus, Benedikt Asbach et al. · 2021 · Proceedings of the National Academy of Sciences
  35. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages
    Giovanny J. Martínez-Colón, Kalani Ratnasiri, Richard Chen, Sizun Jiang, ELIZABETH J. ZANLEY, Arjun Rustagi, Renu Verma, Han M. Chen, Jason Randolph Andrews, Kirsten D. Mertz et al. · 2022 · Science Translational Medicine
  36. Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage
    Stefanie Deinhardt‐Emmer, Daniel Wittschieber, Juliane Sanft, Sandra Kleemann, Stefan Elschner, Karoline Frieda Haupt, Vanessa Vau, Clio Häring, Jürgen Rödel, Andreas Henke et al. · 2021 · eLife
  37. Vitamin D supplementation for the treatment of COVID-19: a living systematic review
    Julia Kristin Stroehlein, Julia Wallqvist, Claire Iannizzi, Agata Mikołajewska, Maria‐Inti Metzendorf, Carina Benstoem, Patrick Meybohm, Marie Becker, Nicole Skoetz, Miriam Songa Stegemann et al. · 2021 · Cochrane Database of Systematic Reviews
  38. The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study
    Samantha N. Piekos, Ryan T Roper, Yeon Mi Hwang, Tanya Sorensen, Nathan D Price, Leroy Hood, Jennifer Hadlock · 2022 · The Lancet Digital Health
  39. Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity
    Shaolei Teng, Adebiyi Sobitan, Raina E. Rhoades, Dongxiao Liu, Qiyi Tang · 2020 · Briefings in Bioinformatics
  40. Furin cleavage sites naturally occur in coronaviruses
    Wu, Yiran, Zhao, Suwen · 2021 · Stem Cell Research
  41. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction
    Scott E. Guimond, Courtney J. Mycroft‐West, Neha S. Gandhi, Julia A. Tree, Thuy T. Le, Cosma Mirella Spalluto, María Victoria Humbert, Karen R. Buttigieg, Naomi S. Coombes, Michael J. Elmore et al. · 2022 · ACS Central Science
  42. Cryo-EM structure of SARS-CoV-2 postfusion spike in membrane
    Wei Kang Shi, Yongfei Cai, Haisun Zhu, Hanqin Peng, Jewel E. Voyer, Sophia Rits‐Volloch, Hong Cao, Megan L. Mayer, Kangkang Song, Chen Xu et al. · 2023 · Nature
  43. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity
    Jinghua Lu, Peter D. Sun · 2020 · Journal of Biological Chemistry
  44. Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution
    Shuyuan Zhang, Shuyuan Qiao, Jinfang Yu, Jianwei Zeng, Sisi Shan, Long Tian, Jun Lan, Linqi Zhang, Xinquan Wang · 2021 · Nature Communications
  45. SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance
    Yifei Guo, Jiajia Han, Yao Zhang, Jingjing He, Weien Yu, Xueyun Zhang, Jingwen Wu, Shenyan Zhang, Yide Kong, Yue Guo et al. · 2022 · Frontiers in Immunology
  46. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
    H. M. Mengist, Arnaud John Kombe Kombe, D. Mekonnen, Abtie Abebaw, Melese Getachew, Teng-Chuan Jin · 2021 · Seminars in Immunology
  47. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors
    Alfonso Trezza, Daniele Iovinelli, Annalisa Santucci, Filippo Prischi, Ottavia Spiga · 2020 · Scientific Reports
  48. Structures of a deltacoronavirus spike protein bound to porcine and human receptors
    Weiwei Ji, Qi Peng, Xueqiong Fang, Zehou Li, Yaxin Li, Cunfa Xu, Shuqing Zhao, Jizong Li, Rong Chen, Guoxiang Mo et al. · 2022 · Nature Communications
  49. Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor
    Boyu Pan, Senbiao Fang, Ju Zhang, Ya Pan, Han Liu, Yun Wang, Min Li, Liren Liu · 2020 · Computational and Structural Biotechnology Journal
  50. Optical technologies for the detection of viruses like COVID-19: Progress and prospects
    Jijo Lukose, Santhosh Chidangil, Sajan Daniel George · 2021 · Biosensors and Bioelectronics
  51. A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
    Md. Mijanur Rahman, Md. Habib Ullah Masum, Shah Wajed, Asma Talukder · 2022 · VirusDisease
  52. Covid-19: the renin–angiotensin system imbalance hypothesis
    Katharina Lanza, Lucas Giandoni Perez, Larissa Braga Costa, Thiago Macedo e Cordeiro, Vitria A. Palmeira, Victor Teatini Ribeiro, Ana Cristina Simões e Silva · 2020 · Clinical Science
  53. SARS-CoV-2 spike protein–induced cell fusion activates the cGAS-STING pathway and the interferon response
    Xiaoman Liu, Wei Ping Liang, Fengwen Xu, Fei Zhao, Yu Huang, Zhangling Fan, Shan Mei, Yamei Hu, Linxuan Zhai, Justin Guo et al. · 2022 · Science Signaling
  54. Current Strategies of Antiviral Drug Discovery for COVID-19
    Miao Mei, Xu Tan · 2021 · Frontiers in Molecular Biosciences
  55. Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis
    Evangelou, Konstantinos, Veroutis, Dimitris, Paschalaki, Koralia, Foukas, Periklis G., Lagopati, Nefeli, Dimitriou, Marios, Papaspyropoulos, Angelos, Konda, Bindu, Hazapis, Orsalia, Polyzou, Aikaterini et al. · 2022 · European Respiratory Journal
  56. Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
    Carlota Dobaño, Rebeca Santano, Alfons Jiménez, Marta Vidal, Jordi Chi, Natalia Rodrigo Melero, Matija Popovic, Rubén López-Aladid, Laia Fernández‐Barat, Marta Tortajada et al. · 2021 · Translational research
  57. Cryo-EM structure of the SARS-CoV-2 Omicron spike
    Gabriele Cerutti, Yicheng Guo, Lihong Liu, Liyuan Liu, Zhening Zhang, Yang Luo, Yiming Huang, Harris H. Wang, David D. Ho, Zizhang Sheng et al. · 2022 · Cell Reports
  58. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
    Tingting Li, Hongmin Cai, Hebang Yao, Bingjie Zhou, Ning Zhang, Martje Fentener van Vlissingen, Thijs Kuiken, Wenyu Han, Corine H. GeurtsvanKessel, Yuhuan Gong et al. · 2021 · Nature Communications
  59. Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important?
    Gary Wong, Yuhai Bi, Qi-Hui Wang, Xin-Wen Chen, Zhigang Zhang, Yong‐Gang Yao · 2020 · 动物学研究
  60. In silico Drug Repurposing for COVID‐19: Targeting SARS‐CoV‐2 Proteins through Docking and Consensus Ranking
    Claudio N. Cavasotto, Juan I. Di Filippo · 2020 · Molecular Informatics
  61. The epigenetic implication in coronavirus infection and therapy
    Sandra Atlante, Alessia Mongelli, Veronica Barbi, Fabio Martelli, Antonella Farsetti, Carlo Gaetano · 2020 · Clinical Epigenetics
  62. Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2
    Marina Johnson, Helen R. Wagstaffe, Kimberly C Gilmour, Annabelle Mai, Joanna E. A. Lewis, Adam Hunt, Jake Sirr, Christopher Bengt, Louis Grandjean, David Goldblatt · 2020 · Journal of Clinical Virology
  63. Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain
    Adriana Carino, Federica Moraca, Bianca Fiorillo, Silvia Marchianò, Valentina Sepe, Michele Biagioli, Claudia Finamore, Silvia Bozza, Daniela Francisci, Eleonora Distrutti et al. · 2020 · Frontiers in Chemistry
  64. SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals
    Cecilie Bo Hansen, Ida Jarlhelt, Laura Pérez‐Alós, Lone Hummelshøj Landsy, Mette Loftager, Anne Rosbjerg, Charlotte Helgstrand, Jais Rose Bjelke, Thomas Egebjerg, Joseph G. Jardine et al. · 2020 · The Journal of Immunology
  65. Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis
    Massimiliano Calabrese, Paolo Preziosa, Antonio Scalfari, Elisa Colato, Damiano Marastoni, Martina Absinta, Marco Battaglini, Nicola De Stefano, Massimiliano Di Filippo, Simon Hametner et al. · 2024 · Annals of Neurology
  66. The acid sphingomyelinase/ceramide system in COVID-19
    Johannes Kornhuber, Nicolas Hoertel, Erich Gulbins · 2021 · Molecular Psychiatry
  67. From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World
    Mickensone Andre, Lee Seng Lau, Marissa D. Pokharel, Julian Ramelow, Florida Owens, Joseph Souchak, Juliet Akkaoui, Evan Ales, Harry H Brown, Rajib Kumar Shil et al. · 2023 · Biology
  68. ACE2 and gut amino acid transport.
    S. Camargo, R. Vuille-Dit-Bille, Chantal F. Meier, F. Verrey · 2020 · Clinical science
  69. Animal models for COVID-19: advances, gaps and perspectives
    Changfa Fan, Yong Wu, Rui Xiong, Yuansong Yang, Chen Ling, Susu Liu, Shunan Liu, Youchun Wang · 2022 · Signal Transduction and Targeted Therapy
  70. Evaluation of SARS-CoV-2 in Tears of Patients with Moderate to Severe COVID-19
    Ritu Arora, Ruchi Goel, Sumit Kumar, Mohit Chhabra, Sonal Saxena, Vikas Manchanda, Palak Pumma · 2020 · Ophthalmology
  71. Targeting Proteases for Treating COVID-19
    Binquan Luan, Tien Huynh, Xuemei M. Cheng, Ganhui Lan, Haoran Wang · 2020 · Journal of Proteome Research
  72. Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2
    Yixin Xie, Chitra B. Karki, Dan Du, Haotian Li, Jun Wang, Adebiyi Sobitan, Shaolei Teng, Qiyi Tang, Lin Li · 2020 · Frontiers in Molecular Biosciences
  73. Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach
    Selvaraj Alagu Lakshmi, Rajamohamed Beema Shafreen, Arumugam Priya, Shunmugiah Karutha Pandian · 2020 · Journal of Biomolecular Structure and Dynamics
  74. SARS-CoV-2 Antiviral Therapy
    Kaiming Tao, Philip L. Tzou, Janin Nouhin, Hector Fabio Bonilla, Prasanna Jagannathan, Robert W. Shafer · 2021 · Clinical Microbiology Reviews
  75. Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
    D. Meekins, N. Gaudreault, J. Richt · 2021 · Viruses
  76. ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
    Federica Saponaro, Grazia Rutigliano, Simona Sestito, Lavinia Bandini, Barbara Storti, Ranieri Bizzarri, Riccardo Zucchi · 2020 · Frontiers in Molecular Biosciences
  77. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry
    Dingqi Zhang, Sami Hamdoun, Ruihong Chen, Lijun Yang, Chi Kio Ip, Yuan Qing Qu, Runfeng Li, Haiming Jiang, Zifeng Yang, Sookja Kim Chung et al. · 2021 · Pharmacological Research
  78. Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens
    Carlota Dobaño, Marta Vidal, Rebeca Santano, Alfons Jiménez, Jordi Chi, Diana Barrios, Gemma Ruiz‐Olalla, Natalia Rodrigo Melero, Carlo Carolis, Daniel Parras et al. · 2020 · Journal of Clinical Microbiology
  79. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
    2021
  80. Global Spread of SARS-CoV-2 Subtype with Spike Protein Mutation D614G is Shaped by Human Genomic Variations that Regulate Expression of TMPRSS2 and MX1 Genes
    Chandrika Bhattacharyya, Chitrarpita Das, Arnab Ghosh, Animesh Kumar Singh, Souvik Mukherjee, Partha Pratim Majumder, Analabha Basu, Nidhan K. Biswas · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  81. Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia
    Enrrico Bloise, Jianhong Zhang, Jittanan Nakpu, Hirotaka Hamada, Caroline Dunk, Siliang Li, Güínever E. Império, Lubna Nadeem, Mark Kibschull, Phetcharawan Lye et al. · 2020 · American Journal of Obstetrics and Gynecology
  82. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
    Chao Zhang, Yifan Wang, Yuanfei Zhu, Caixuan Liu, Chenjian Gu, Shiqi Xu, Yalei Wang, Yu Zhou, Yanxing Wang, Wenyu Han et al. · 2021 · Nature Communications
  83. HVIDB: a comprehensive database for human–virus protein–protein interactions
    Xiaodi Yang, Xianyi Lian, Chen Fu, Stefan Wuchty, Shiping Yang, Ziding Zhang · 2020 · Briefings in Bioinformatics
  84. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19
    Saman Yasamineh, Hesam Ghafouri Kalajahi, Pooneh Yasamineh, Yalda Yazdani, Omid Gholizadeh, Raheleh Tabatabaie, Hamed Afkhami, Fatemeh Davodabadi, Alireza Khanalipour farkhad, Daryoush Pahlevan et al. · 2022 · Journal of Nanobiotechnology
  85. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
    Shen Wang, Wujian Li, Zhenshan Wang, Wanying Yang, Entao Li, Xianzhu Xia, Feihu Yan, Sandra Chiu · 2024 · Signal Transduction and Targeted Therapy
  86. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19
    Chandrabose Selvaraj, Dhurvas Chandrasekaran Dinesh, Umesh Panwar, Rajaram Abhirami, Evžen Bouřa, Sanjeev Kumar Singh · 2020 · Journal of Biomolecular Structure and Dynamics
  87. Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach
    Ziyad Tariq Muhseen, Alaa R. Hameed, Halah M. H. Al-Hasani, Muhammad Tahir ul Qamar, Guanglin Li · 2020 · Journal of Molecular Liquids
  88. Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies
    Thomas Guettler, Metin Aksu, Antje Dickmanns, Kim M. Stegmann, Kathrin Gregor, Renate Rees, Waltraud Taxer, Oleh Rymarenko, Jürgen Schünemann, Christian Dienemann et al. · 2021 · The EMBO Journal
  89. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3
    Min Huang, Lili Wu, Anqi Zheng, Yufeng Xie, Qingwen He, Xiaoyu Rong, Pu Han, Pei Du, Pengcheng Han, Zengyuan Zhang et al. · 2022 · Immunity
  90. Crystal structure of SARS-CoV-2 nsp10/nsp16 2′-O-methylase and its implication on antiviral drug design
    Sheng Lin, Hua Chen, Fei Ye, Zimin Chen, Fanli Yang, Yue Zheng, Yu Cao, Jingxin Qiao, Shengyong Yang, Guangwen Lu · 2020 · Signal Transduction and Targeted Therapy
  91. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
    Konstantinos E. Farsalinos, Elias Eliopoulos, Demetres D. Leonidas, Georgios E. Papadopoulos, Socrates J. Tzartos, Konstantinos A. Poulas · 2020 · International Journal of Molecular Sciences
  92. Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences
    Elena Campione, Caterina Lanna, Terenzio Cosio, Luigi Rosa, Maria Pia Conte, Federico Iacovelli, Alice Romeo, Mattia Falconi, Claudia Del Vecchio, Elisa Franchin et al. · 2021 · Frontiers in Pharmacology
  93. COVID-19 and the endothelium
    Friedrich Jung, Anne Krüger‐Genge, Ralf P. Franke, Frank T. Hufert, J.‐H. Küpper · 2020 · Clinical Hemorheology and Microcirculation
  94. Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor
    Jinbiao Liu, Brittany H. Bodnar, Fengzhen Meng, Adil I. Khan, Xu Wang, Guangxiang George Luo, Sami Saribas, Tao Wang, Saroj Chandra Lohani, Peng Wang et al. · 2021 · Cell & Bioscience
  95. Antiviral Drug Discovery for the Treatment of COVID-19 Infections
    Teresa I. Ng, Ivan Correia, Jane Seagal, David A. DeGoey, Michael R. Schrimpf, David J. Hardee, Elizabeth L. Noey, Warren M. Kati · 2022 · Viruses
  96. SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets
    Jayalakshmi Vallamkondu, Albin A John, Willayat Yousuf Wani, S. Ramadevi, Kishore Kumar Jella, P. Hemachandra Reddy, Ramesh J. L. Kandimalla · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  97. A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids
    Jan A Wysocki, Minghao Ye, Luise Hassler, Ashwani Gupta, Yuguo Wang, Vlad Nicoleascu, Glenn C. Randall, Jason A. Wertheim, DANIEL C. BATLLE · 2021 · Journal of the American Society of Nephrology
  98. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
    Federico Bertoglio, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Leila Abassi, Thomas Klünemann, Ulfert Rand, Doris Meier, Nora Langreder, Stephan Steinke et al. · 2021 · Cell Reports
  99. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
    Federico Bertoglio, Doris Meier, Nora Langreder, Stephan Steinke, Ulfert Rand, Luca Simonelli, Philip Alexander Heine, Rico Ballmann, Kai-Thomas Schneider, Kristian Daniel Ralph Roth et al. · 2021 · Nature Communications
  100. Targeting Lipid Rafts as a Strategy Against Coronavirus
    Maurizio Sorice, Roberta Misasi, Gloria Riitano, Valeria Manganelli, Stefano Martellucci, Agostina Longo, Tina Garofalo, Vincenzo Mattei · 2021 · Frontiers in Cell and Developmental Biology